**Polygonatum sibiricum** polysaccharide alleviates inflammatory cytokines and promotes glucose uptake in high-glucose- and high-insulin-induced 3T3-L1 adipocytes by promoting Nrf2 expression

JIALUO CAI1, YILIN ZHU2*, YAJIE ZUO3, QIAOZHEN TONG4,5, ZHIGUO ZHANG3, LEI YANG6, XIAOPING LI1 and GANGQIANG YI5

1Preventive Treatment of Disease Center, The First Hospital of Hunan University of Chinese Medicine; 2Student Affairs Office, Hunan University of Chinese Medicine; 3Department of Pharmacy, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410000; 4Yueyang Affiliated Hospital of Hunan University of Chinese Medicine, Yueyang, Hunan 414000; 5Hunan University of Chinese Medicine; 6Preparation Center, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410000, P.R. China

Received April 17, 2019; Accepted July 31, 2019

DOI: 10.3892/mmr.2019.10626

**Abstract.** *Polygonatum sibiricum* polysaccharide (PSP) has been shown to alleviate hyperglycemia and reduce oxidative stress to delay the progression of diabetic retinopathy and cataracts. However, its role and underlying mechanisms in regulating type 2 diabetes mellitus (T2DM) remain unclear. Nuclear factor erythroid 2-related factor 2 (Nrf2) activation plays a protective role in T2DM. The present study focused on the effect of PSP on inflammatory cytokine secretion and Nrf2 expression in the adipocytes of T2DM patients. In this study, high-glucose- and high-insulin-induced 3T3-L1 adipocytes were used to mimic insulin-resistant (IR)-3T3-L1 adipocytes. Furthermore, the effect and underlying mechanisms of PSP on inflammation and glucose uptake in IR-3T3-L1 adipocytes were investigated. The present study found that proliferation after 50, 100 and 250 µg/ml PSP treatment had no significant change in normal 3T3-L1 adipocytes. A total of 50, 100 and 250 µg/ml of PSP also alleviated IL-1β, IL-6, and TNF-α levels and promoted proliferation, glucose uptake, and glucose transporter 4 expression in IR-3T3-L1 adipocytes. Furthermore, 50, 100 and 250 µg/ml PSP promoted Nrf2 and HO-1 expression. However, silencing Nrf2 expression reversed the effect of 100 µg/ml PSP in IR-3T3-L1 adipocytes. In conclusion, these results suggest that PSP alleviates inflammatory cytokines and promotes glucose uptake in IR-3T3-L1 adipocytes by promoting Nrf2 expression. PSP may be a potential therapeutic agent for T2DM treatment by promoting Nrf2 expression.

**Introduction**

Type 2 diabetes mellitus (T2DM), a serious public health issue worldwide, is harmful to important organs such as the eyes, kidneys and nerves due to insulin resistance (IR) and high glucose concentrations in the blood (1). Currently, T2DM treatment has advanced considerably; however, the available treatments remain limited. Numerous studies have strongly associated obesity with T2DM (2,3). Notably, dysfunctional adipocytes, regulated the excessive secretion of inflammatory cytokines, represent a key link between obesity and IR (4,5). Moreover, clinical and epidemiological studies also associated the development of T2DM with inflammatory factors, which are new targets for T2DM treatment (6). Therefore, it will be important to identify new drugs that can inhibit proinflammatory adipocytokine secretion in T2DM.

Traditional Chinese medicines (TCMs) have exhibited great efficacy in treating T2DM with good application prospects. Chen et al (6) found that berberine markedly prevented the development of T2DM by modulating *Bifidobacterium* species and inhibiting inflammation and development of diabetic nephropathy. Furthermore, puerarin was found to reduce inflammation and blood glucose levels and improve IR, thereby improving the development of T2DM and DM.
complications (7). The Huang-Lian-Jie-Du decoction, a TCM prescription, also regulated gut microbiota and improved hyperglycemia and IR in T2DM (8). Polygonatum sibiricum polysaccharide (PSP) is isolated from Polygonatum sibiricum. Additionally, water-extraction of PSP are of low toxicity and are suitable for long-term administration (9). The hot water-extraction of PSP product is composed of different ratios of monosaccharides, including rhamnose, mannose, xylose, arabinose, fucose, galactose, glucose, galacturonic acid and glucuronic acid (10,11). Polygonatum sibiricum and PSP have many pharmacological applications and biological activities and has used to treat a number of diseases (9,10). It is reported that PSP could inhibit inflammation such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α expression in lipopolysaccharide-treatment RAW264.7, ovariectomized rat, acute heart failure rats, suggest that PSP had anti-inflammation effect (12-14). Moreover, PSP alleviated hyperglycemia and reduced oxidative stress to delay the progression of diabetic retinopathy and cataracts (15,16). Therefore, more studies are needed to further confirm the role and mechanism of PSP in regulating diabetes, especially T2DM. However, the regulating effect of PSP on inflammation and glucose uptake in regulating T2DM remains unclear.

Nrf2 plays a key role in regulating inflammation (17). Nrf2 and Kelch-like ECH-associated protein 1 are uncoupled to allow Nrf2 localization in the nucleus, then Nrf2 binds to the heme oxygenase 1 (HO-1) promoter to promote HO-1 expression, which can activate nuclear factor-kB and promote pro-inflammatory secretion (18-20). Nrf2 could regulate metabolic homeostasis and insulin action and it may serve as a potential drug target for diabetes and treatment of its complications (21). However, whether PSP can improve the IR of 3T3-L1 adipocytes through Nrf2 is still unclear.

In this study, the effect of PSP on inflammatory cytokine secretion and glucose uptake in high-glucose- and high-insulin-induced 3T3-L1 adipocytes to mimic IR-3T3-L1 adipocytes was focused on. Furthermore, the underlying mechanisms of PSP on inflammation and glucose uptake in IR-3T3-L1 adipocytes was investigated. In present study, whether PSP alleviated inflammatory cytokines and promotes glucose uptake in high-glucose- and high-insulin-induced 3T3-L1 adipocytes by promoting Nrf2 expression was investigated.

Materials and methods

The compete experimental schedule is shown in Fig. 1.

Drugs. PSP was purchased from Shaanxi Undersun Biomedtech Co., Ltd. PSP was pretreated and extracted using a hot water extraction method. Its purity was 92% according to the certificate of analysis. PSP was dissolved in 1 mg/ml of 0.1 mol/l PBS prior to use.

Cell culture and establishment of an IR model. 3T3-L1 pre-adipocytes (American Type Cell Culture) were cultured and induced to differentiate into mature adipocytes as described previously (22). To establish an IR model (IR-3T3-L1 adipocytes), 3T3-L1 adipocytes were cultured for 24 h at 37°C in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 1 µmol/l insulin and 25 mmol/l glucose.

Proliferation assay. Proliferation of IR-3T3-L1 adipocytes was measured using Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) assay. In total, 1x104 IR-3T3-L1 adipocytes/well were cultured and treated with 0, 50, 100, 250, 500 and 1,000 µg/ml of PSP for 12, 24 and 48 h. CCK-8 (10 µl) was then added and incubated for 4 h. Absorbance was detected at 450 nm using a microplate absorbance reader (R&D Systems, Inc.). Each experiment was repeated thrice.

Inflammatory cytokine and glucose assay. IL-1β, IL-6 and TNF-α levels in culture supernatants were measured using ELISA according to the protocol supplied by the manufacturer (cat. nos. EK101B2-96T, EK1062-96T and EK1822-96T; Hangzhou MultiSciences (Lianke) Biotech, Co., Ltd.). Glucose levels in culture supernatant were measured using a Glucose Assay kit (Nanjing Jiancheng Bioengineering Institute). Each experiment was repeated thrice.

Western blotting. 3T3-L1 adipocytes were washed twice with ice-cold PBS and lysed in ice-cold radioimmunoprecipitation assay buffer containing 1 mmol/l of PMSF and a cocktail of protease inhibitors (1:100; Beyotime Institute of Biotechnology). Next, the total protein concentration of all tissue lysates was determined with a bicinchoninic acid assay protein assay kit (Pierce; Thermo Fisher Scientific, Inc.). Briefly, 20 µg protein samples were separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes (Pall Corporation), and membranes were blocked with PBS containing 10% non-fat dry milk, overnight at 4°C. Membranes were then incubated for 12 h at 4°C with antibodies against Nrf2 (1:1,000; cat. no. ab62352; Abcam), HO-1 (1:2,000; cat. no. ab189491; Abcam) and glucose transporter 4 (GLUT-4; 1:2,000; cat. no. ab205718; Abcam) for 1 h at 25°C. Finally, membranes were washed and incubated with a goat anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (1:10,000; cat. no. ab205718; Abcam). Membranes were then incubated for 2 h at 4°C with antibody bodies against Nrf2 (1:1,000; cat. no. Ab62352; Abcam), HO-1 (1:2,000; cat. no. ab189491; Abcam) and glucose transporter 4 (GLUT-4; 1:2,000; cat. no. ab654; Abcam). Next, membranes were washed and incubated with a goat anti-rabbit IgG horse-radish peroxidase-conjugated secondary antibody (1:10,000; cat. no. ab205718; Abcam) for 1 h at 25°C. Finally, membranes were visualized using an ECL substrate kit (GE Healthcare Life Sciences) and densitometric analysis was performed using Image Pro-Plus 6.0 software (Media Cybernetics, Inc.). β-actin was used as a reference protein (1:5,000; cat. no. ab8227; Abcam).

Nrf2 small interfering RNA (siRNA) transfection. siRNAs for Nrf2 (si-Nrf2, 5'-AGUCAUGAAGCUACACTT-3') and negative control [si-negative control (NC), 5'-UUUCUG GAACGUGACGUUGTT-3'-5'] were synthesized by Shanghai GenePharma. IR-3T3-L1 adipocytes were plated at 50% confluence and transfected with 200 nM si-Nrf2 or si-NC using Lipofectamine® 3000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.). At 48 h after transfection, cells were treated with 100 µg/ml PSP for 48 h.

Statistical analysis. SPSS 19.0 software (IBM, Corps.) was used to perform all statistical analyses. Continuous variables are presented as the mean ± standard deviation. Significance of the differences among multiple groups was analyzed using
one-way analysis of variance followed by a post-hoc least significant difference test. The significance difference between 2 groups (normal group and ir model group; si-nc group and si-nrf2 group) was analyzed via the unpaired t-test. P<0.05 were considered to indicate statistically significant.

Results

Effects of PSP on 3T3-L1 adipocyte proliferation. To determine the effect PSP on the proliferation of normal 3T3-L1 adipocytes, adipocytes were treated with 0, 50, 100, 250, 500 and 1,000 µg/ml PSP. The CCK-8 assay results showed that 50, 100 and 250 µg/ml PSP had no significant effect on the survival of normal 3T3-L1 adipocytes at 12, 24 and 48 h, whereas 500 and 1,000 µg/ml PSP treatments significantly inhibited the survival of normal 3T3-L1 adipocytes in a time-dependent manner from 24 h onwards (P<0.05; Fig. 2). As per the results, 50, 100 and 250 µg/ml PSP were chosen for subsequent experiments.

CCK-8 assay results showed that IR significantly inhibited the proliferation of 3T3-L1 adipocytes, whereas 50, 100 and 250 µg/ml PSP treatment significantly alleviated the IR effect in IR-3T3-L1 adipocytes (P<0.05; Fig. 3A). The glucose in the culture medium was significantly increased in the IR model group compared with in the normal cell group and was significantly decreased in the 50, 100 and 250 µg/ml PSP treatment group compared with in the IR model group (P<0.001; Fig. 3B). The results suggested that IR significantly inhibited the glucose uptake of 3T3-L1 adipocytes, whereas 50, 100 and 250 µg/ml PSP treatment significantly alleviated the IR effect in IR-3T3-L1 adipocytes. Moreover, western blot results showed that IR significantly inhibited GLUT-4 expression, whereas 50, 100 and 250 µg/ml PSP treatment alleviated this effect in IR-3T3-L1 adipocytes (P<0.001; Fig. 3C and 3D). Additionally, proliferation, glucose uptake, GLUT-4 expression exhibited no obvious change between 50, 100 and 250 µg/ml PSP treatment groups.

PSP treatment alleviates inflammatory cytokines in IR-3T3-L1 adipocytes. IL-1β, IL-6 and TNF-α levels in the culture supernatant were measured using ELISAs. The results showed that IL-1β, IL-6 and TNF-α levels were significantly increased in
the IR model group compared with in the normal cell group, and were significantly decreased in the 50, 100 and 250 μg/ml PSP treatment group compared with the IR model group (P<0.001; Fig. 4). Furthermore, IL-1β, IL-6 and TNF-α levels exhibited no obvious change between 50, 100 and 250 μg/ml PSP treatment groups.

**PSP treatment promotes Nrf2 expression in IR-3T3-L1 adipocytes.** Next, the underlying mechanism of PSP in IR-3T3-L1 adipocytes was investigated. Western blotting results showed that IR treatment significantly inhibited Nrf2 and HO-1 expression in 3T3-L1 adipocytes (P<0.001; Fig. 5). However, 50, 100 and 250 μg/ml PSP treatment significantly

---

**Figure 3.** A total of 50, 100 and 250 μg/ml PSP treatment improves the proliferation, glucose uptake, and GLUT-4 expression of IR-3T3-L1 adipocytes after treated at 48 h. (A) The proliferation was measured by Cell Counting Kit-8, (B) Glucose concentration in the culture supernatant were measured using a Glucose Assay kit. The smaller the glucose concentration, the better the glucose uptake. (C) GLUT-4 expression in IR-3T3-L1 adipocytes was measured by western blot. (D) The bar graph represents the quantification of respective GLUT-4 protein expression. *P<0.05 and **P<0.001 vs. normal cell; #P<0.05 and ###P<0.001 vs. IR model. PSP, Polygonatum sibiricum polysaccharide; GluT4, glucose transporter 4; IR, insulin resistant.

**Figure 4.** IL-1β, IL-6 and TNF-α expression levels are significantly inhibited by PSP treatment in 3T3-L1 adipocyte. IL-1β, IL-6, and TNF-α levels in the culture supernatant were measured by ELISA after 50, 100 and 250 μg/ml PSP treatment at 48 h in 3T3-L1 adipocytes. ***P<0.001 vs. normal cell; ###P<0.001 vs. IR model. PSP, Polygonatum sibiricum polysaccharide; IL, interleukin; TNF, tumor necrosis factor; IR, insulin resistant.
promoted Nrf2 and HO-1 expression in IR-3T3-L1 adipocytes and reversed the effect of IR on Nrf2 and HO-1 expression (P<0.001; Fig. 5).

Silencing Nrf2 expression reverses the effects of PSP on cell survival and glucose uptake in IR-3T3-L1 adipocytes. To further elucidate the role of Nrf2 in 100 µg/ml PSP-treated IR-3T3-L1 adipocytes, Nrf2 expression was knocked down using si-Nrf2 in IR-3T3-L1 adipocytes. Nrf2 expression was inhibited by si-Nrf2 when compared with si-NC (Fig. 6A). Notably, silencing Nrf2 significantly repressed the proliferation of IR-3T3-L1 adipocytes after 100 µg/ml PSP treatment (P<0.05; Fig. 6B). The glucose in the culture medium was also significantly increased in the si-Nrf2 group compared with the si-NC group (P<0.001; Fig. 6C) and HO-1 and GLUT-4 expression was inhibited in the si-Nrf2 group when compared with the si-NC group (Fig. 6D). The results suggested that silencing Nrf2 significantly inhibited the glucose uptake of 3T3-L1 adipocytes, thereby reversing the effect of 100 µg/ml PSP.
Silencing Nrf2 expression reverses the effects of PSP on inflammatory cytokines in IR-3T3-L1 adipocytes. IL-1β, IL-6, and TNF-α levels were measured using ELISAs. The results showed that silencing Nrf2 expression significantly promoted IL-1β, IL-6, and TNF-α levels after 100 µg/ml PSP treatment in IR-3T3-L1 adipocytes (P<0.001; Fig. 7). The schematic diagram about PSP-mediated regulation of inflammatory cytokines in high-glucose- and high-insulin-induced 3T3-L1 adipocytes is presented in Fig. 8.

Discussion

Currently, patients with T2DM are limited in their options for effective therapeutic drugs. Hence, it is important to find novel drugs with respect to T2DM therapy. In this study, it was found that 50, 100 and 250 µg/ml PSP treatments exhibited no significant effects on the survival of normal 3T3-L1 adipocytes; however, the PSP treatments facilitated cell survival, promoted glucose uptake, and inhibited inflammatory expression in IR-3T3-L1 adipocytes. PSP treatment also promoted Nrf2 expression. Reciprocally, silencing Nrf2 expression reduced cell survival, inhibited glucose uptake and promoted inflammatory expression in PSP-treated IR-3T3-L1 adipocytes. Therefore, PSP was verified to play a potential therapeutic effect in T2DM.

The risk of T2DM has been strongly associated with high levels of inflammatory cytokines such as IL-1β, IL-6, TNF-α and c-reactive protein (23). Dysfunctional adipocytes produce excessive inflammatory cytokines thereby causing IR in skeletal muscle and adipocytes cells and hepatocytes (22,24). IR inhibited glucose uptake by reduced GLUT 4 expression (25). Additionally, obesity-induced IR via the induction of adipocyte inflammation can inhibit glucose uptake and cell proliferation and in adipocytes (26). These above results showed that inflammation can inhibit cell survival and cause IR which can inhibit glucose uptake by reduced GLUT 4 expression. Therefore, an important strategy to treat T2DM is to prevent inflammation. In this study, it was found that IL-1β, IL-6 and TNF-α levels were upregulated, whereas GLUT-4 expression and glucose uptake were inhibited in IR-3T3-L1 adipocytes, all of which simulate the IR-induced inflammatory microenvironment around adipocytes. It was also found that PSP treatment downregulated IL-1β, IL-6 and TNF-α levels, facilitated cell survival, and promoted GLUT-4 expression and glucose uptake in IR-3T3-L1 adipocytes. These results suggest that PSP reduces the secretion of inflammatory cytokines which can promote GLUT-4 expression and glucose uptake in IR-3T3-L1 adipocytes and alleviates the IR of 3T3-L1 adipocytes. Similar to the results of the present study that indicated PSP's role in anti-inflammation, previous studies also found that PSP played anti-inflammatory roles via IL-1β, IL-6 and TNF-α (11,14). PSP also delayed the progression of diabetic retinopathy and cataracts (15,16), further indicating its therapeutic potential in T2DM.

Nrf2 plays a protective role in T2DM. For example, Actinidia chinensis (Planch.) has been demonstrated to prevent the onset of T2DM by promoting Nrf2 expression, which in-turn improves oxidant and inflammation levels (27). The development of novel and effective Nrf2 activators may provide novel therapeutic drugs for T2DM treatment. The Nrf2/HO-1 signaling pathway is linked to obesity, pancreatic β cell damage, IR and glucose metabolism disorders (28). Anthocyanins could ameliorate diabetic-induced retinal cell damage through the Nrf2 / HO-1 signaling pathway (29). In this study, it was found that PSP treatment promoted Nrf2
and HO-1 expression in IR-3T3-L1 adipocytes. Silencing Nrf2 expression promoted IL-1β, IL-6 and TNF-α secretion and inhibited proliferation, glucose uptake, and HO-1 and GLUT-4 expression, thereby reversing the therapeutic effect of PSP in IR-3T3-L1 adipocytes. These results suggest that PSP alleviates inflammatory cytokines and promotes glucose uptake in IR-3T3-L1 adipocytes by promoting Nrf2 expression.

The present study had two limitations. Firstly, the effects and mechanisms of PSP on T2DM needs to be studied more comprehensively. Secondly, the therapeutic effect of PSP also needs to be clarified in experimental animals and clinical trials.

In conclusion, the present study suggested that PSP has the potential to be used in the treatment of T2DM owing to its inducing effect on Nrf2 expression. However, comprehensive studies are needed that detail the therapeutic effects and mechanisms of PSP in experimental animals and clinical trials in the future.

Acknowledgements
Not applicable.

Funding
The present study was supported by grants from the youth program of the Natural Science Foundation of Hunan province, China (grant no. 2019JJS041), the Natural Science Foundation of Hunan University of Chinese Medicine, China (grant no. ZYYDX201740) and the State Administration of Traditional Chinese Medicine of the People's Republic of China Construction Project of Zhang Zhiguo Heritage Studio Related to the Old Chinese Medicine Experts [grant no. (2016)42].

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
JC, YZh, XL and GY conceived and designed the present study. JC, YZh, YZu, QT and ZZ developed the methodology. JC, YZh and LY completed the experiment and collected the data. JC, YZh, YZu, QT and ZZ analyzed and interpreted the data. JC and YZh drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.


24. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J and Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17: 4-12, 2006.


